On Sunday, AstraZeneca Plc (AZN) released results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial in previously untreated patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletion or exon 21 L858R mutations.
Patients were treated with Tagrisso (osimertinib) with the addition of chemotherapy plus cisplatin or carboplatin every three weeks for four cycles, followed by Tagrisso with pemetrexed maintenance every three weeks.
